Kymera Therapeutics (KYMR) Preferred Stock Liabilities (2019 - 2020)
Kymera Therapeutics (KYMR) posted quarterly Preferred Stock Liabilities of $5.9 million for Q2 2020, down 79.82% quarter-over-quarter from $29.2 million in Q4 2019.
Kymera Therapeutics (KYMR) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Preferred Stock Liabilities for 2 consecutive years, with $5.9 million the latest figure, recorded in Q2 2020.
- In Q2 2020, Preferred Stock Liabilities changed N/A year-over-year to $5.9 million; the TTM figure through Jun 2020 stood at $5.9 million (changed N/A YoY), while the FY2019 annual figure was $29.2 million, changed N/A from the prior year.
- Preferred Stock Liabilities eased to $5.9 million in Q2 2020 per KYMR's latest filing, from $29.2 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $29.2 million in Q4 2019 and bottomed at $5.9 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 5.90 Mn |
| Dec 31, 2019 | 29.24 Mn |
| Sep 30, 2019 | 5.90 Mn |